摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-(Cyclohexylmethyl)-3-ethenyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrazole | 654058-99-8

中文名称
——
中文别名
——
英文名称
1-(Cyclohexylmethyl)-3-ethenyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrazole
英文别名
1-(cyclohexylmethyl)-3-ethenyl-5-(4-methylsulfanylphenyl)pyrazole
1-(Cyclohexylmethyl)-3-ethenyl-5-[4-(methylsulfanyl)phenyl]-1H-pyrazole化学式
CAS
654058-99-8
化学式
C19H24N2S
mdl
——
分子量
312.5
InChiKey
SMKUORKNIVENFT-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.5
  • 重原子数:
    22
  • 可旋转键数:
    5
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.42
  • 拓扑面积:
    43.1
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • Cyclooxygenase-2 selective inhibitors, compositions and methods of use
    申请人:NitroMed, Inc.
    公开号:US20040072883A1
    公开(公告)日:2004-04-15
    The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.
    本发明描述了新型环氧合酶2(COX-2)选择性抑制剂和包含至少一种环氧合酶2(COX-2)选择性抑制剂的新型组合物,以及可选地,至少一种捐赠、转移或释放一氧化氮、刺激内源性一氧化氮合成、提高内源性内皮衍生松弛因子平或是一氧化氮合酶底物的化合物,和/或至少一种治疗剂。本发明还提供了包含至少一种COX-2选择性抑制剂、可选地亚硝化和/或亚硝酰化,以及可选地至少一种一氧化氮给体和/或至少一种治疗剂的新型试剂盒。本发明的新型环氧合酶2选择性抑制剂可选择性地亚硝化和/或亚硝酰化。本发明还提供了治疗炎症、疼痛和发热的方法;用于治疗和/或改善COX-2选择性抑制剂的胃肠道特性;促进伤口愈合的方法;用于治疗和/或预防肾脏和/或呼吸毒性的方法;用于治疗和/或预防由于环氧合酶-2平升高而引起的其他疾病的方法;以及用于改善COX-2选择性抑制剂的心血管特性的方法。
  • CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE
    申请人:Nitromed, Inc.
    公开号:EP1542972A2
    公开(公告)日:2005-06-22
  • EP1542972A4
    申请人:——
    公开号:EP1542972A4
    公开(公告)日:2008-01-23
  • US7244753B2
    申请人:——
    公开号:US7244753B2
    公开(公告)日:2007-07-17
  • [EN] CYCLOOXYGENASE- 2 SELECTIVE INHIBITORS, COMPOSITIONS AND METHODS OF USE<br/>[FR] INHIBITEURS SELECTIFS DE LA CYCLO-OXYGENASE-2, COMPOSITIONS ET PROCEDES D'UTILISATION
    申请人:NITROMED INC
    公开号:WO2004010945A2
    公开(公告)日:2004-02-05
    The invention describes novel cyclooxygenase 2 (COX-2) selective inhibitors and novel compositions comprising at least one cyclooxygenase 2 (COX-2) selective inhibitor, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium­derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one COX-2 selective inhibitor, optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor, and/or, optionally, at least one therapeutic agent. The novel cyclooxygenase 2 selective inhibitors of the invention can be optionally nitrosated and/or nitrosylated. The invention also provides methods for treating inflammation, pain and fever; for treating and/or improving the gastrointestinal properties of COX-2 selective inhibitors; for facilitating wound healing; for treating and/or preventing renal and/or respiratory toxicity; for treating and/or preventing other disorders resulting from elevated levels of cyclooxygenase-2; and for improving the cardiovascular profile of COX-2 selective inhibitors.
查看更多